|
12 May 2020 |
Dyno Therapeutics Announces Ocular Collaboration with Novartis to Develop Improved Gene Therapies with AAV Vectors based on AI Technology
|
|
12 May 2020 |
bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement
|
|
10 May 2020 |
jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical
|
|
08 May 2020 |
Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers
|
|
08 May 2020 |
Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program
|
|
07 May 2020 |
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors
|
|
06 May 2020 |
Avectas and ONK Therapeutics to Develop Off-the-Shelf Cancer Therapy
|
|
06 May 2020 |
Rebiotix and Ferring Announce World’s First With Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660
|
|
06 May 2020 |
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors
|
|
06 May 2020 |
Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy
|
|
06 May 2020 |
BioCardia Announces Positive Preclinical Results Supporting Investigational New Drug Application for Anti-Inflammatory Cell Therapy in Heart Failure
|
|
06 May 2020 |
Kiadis Pharma announces U.S. FDA approval to start NK-REALM Phase 2 clinical trial for natural killer (NK) cell therapy produced with PM21
|
|
05 May 2020 |
Adverum Biotechnologies Reports Positive Interim Data from Cohorts 1-3 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
|
|
04 May 2020 |
Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19
|
|
01 May 2020 |
Athersys and University Hospitals Cleveland Medical Center Announce Activation of the First Clinical Site for the MACOVIA Study, a Pivotal Phase 2/3 Study Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
|
|
30 Apr 2020 |
Neon Therapeutics Announces Acceptance of European Clinical Trial Authorization Application for NEO-PTC-01
|
|
30 Apr 2020 |
Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease
|
|
30 Apr 2020 |
Phase 2/3 randomized controlled trial of remestemcel-l in 300 patients with COVID-19 acute respiratory distress syndrome begins enrollment
|
|
29 Apr 2020 |
Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers
|
|
29 Apr 2020 |
Gracell Reports Data of First-in-human Clinical Trial for Universal TruUCAR™ GC027 in Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Virtual Annual Meeting
|
|
28 Apr 2020 |
Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19
|
|
28 Apr 2020 |
BioEclipse Receives FDA Clearance of Investigational New Drug Application for CRX100
|
|
27 Apr 2020 |
Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate
|
|
27 Apr 2020 |
Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy in Proof-of-Concept Clinical Trial for Sanfilippo Syndrome (MPS-IIIA)
|
|
24 Apr 2020 |
83% Survival in COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome Treated in New York with Mesoblast’s Cell Therapy Remestemcel-L
|
